News

U.S. regulator warns of blood clotting in J&J vax

Published

on

Johnson & Johnson’s Covid-19 vaccine is being limited by U.S. regulators over blood clotting fears

The J&J jab received initial approval back in February 2021, and is one of the three vaccines being used throughout the United States.

The company’s vaccine has been plagued by a number of issues and setbacks, ultimately leading to competitors Moderna and Pfizer gaining the upper hand.

The U.S. Food and Drug Administration says the shot can still be used in cases where approved COVID-19 vaccines are not accessible or if an individual preferences the J&J version.

Johnson & Johnson says it has updated its vaccine fact sheet to warn about the risk of patients developing a rare but potentially life-threatening blood clot condition.

The FDA says it conducted a wide-ranging investigation into the single-dose Covid-19 jab before issuing the limit.

Trending Now

Exit mobile version